ICU MEDICAL Business Summary

ICU Medical Inc. (ICUI) operates a razor-and-blade business model, generating approximately 60-70% of its revenue through recurring sales of high-attachment disposables and consumables, complemented by capital equipment placements and clinical software services. The company’s operations are divided into three primary segments: Infusion Therapy, which includes needlefree connectors like the Clave and MicroClave; Infusion Systems, featuring large-volume, syringe, and ambulatory pumps such as the Plum 360 and CADD platforms; and Vital Care, which encompasses hemodynamic monitoring, temperature management, and respiratory products. ICU Medical competes directly with large-scale medical technology firms such as Becton, Dickinson and Company (BD), Baxter International, B. Braun, and Edwards Lifesciences, positioning itself as a specialized, safety-focused leader in the infusion therapy market with a highly integrated ecosystem of hardware and consumables. The company was founded in 1984 by Dr. George A. Lopez, an anesthesiologist and inventor who developed the first needlefree IV connector to improve clinician safety. Today, the leadership team is led by Chairman and CEO Vivek Jain, who joined in 2014 with a deep pedigree in the sector, having previously served as a senior executive at CareFusion and McKinsey & Company. Key executives include Chief Financial Officer Brian Bonnell, Chief Operating Officer Christian Voigtlander, and President Daniel Woolson. The company’s board features notable industry veterans such as Lead Independent Director David Greenberg and Elisha Finney. Significant institutional ownership is held by firms like Vanguard and BlackRock, while Pfizer and Smiths Group have historically maintained major equity stakes following the strategic acquisitions of Hospira Infusion Systems and Smiths Medical, respectively.